Home News DuPont celebrates official Opening of Industrial Biosciences’ – Experimental Station

DuPont celebrates official Opening of Industrial Biosciences’ – Experimental Station

225
SHARE

DuPont Industrial Biosciences, A DowDuPont Specialty Products Division business, works with customers across a wide range of industries to make products and industrial processes more efficient and sustainable. Through a unique combination of agriculture, biotechnology, chemistry and material science capabilities, we advance market-driven, bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations.

DuPont has officially opened Industrial Biosciences’ Global Business Headquarters, an experimental station known as building E353 in Wlimington, Delaware. Here, paradigm shift technologies were bred from nylon to DuPont™, Industrial Biosciences’ (IB) Sorona® and Kevlar® to Lycra®.

For all assets related to this proclamation, visit: http://biosciences.dupont.com/grandopening

Mr William Feehery, President DuPont Industrial Biosciences said, “At this new facility, we have hundreds of people working toward a more sustainable future by innovating bio-based solutions that are better, safer and more renewable. These technologies go into products that are used in everyday life. The redesigned and upgraded laboratories and office spaces are incubators for some of DuPont’s most groundbreaking work.”

The researchers at this facility will continue innovation, scientific advancement and bioinformatics for more sustainable products and processes for clients globally.

The E353 renovation focused on modern and advance capabilities which include:
1. Cutting-edge genome editing capabilities using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to accelerate microbial production host development.
2. Microbiological labs to evaluate tailored animal health solutions and to conduct micro-biome science for probiotics product development.
3. Highly leveraged fermentation labs to advance “cell factory” end-to-end development and commercialization.
4. Leading-edge chemistry and bioprocess science and engineering capabilities to establish high-performance biomaterials platforms.